GET DAILY SIGNALSALX Oncology Holdings (ALXO) Drops -21% Over 30 Days Following Equity Financing
Key Takeaways
- ALX Oncology Holdings (ALXO) shares fell roughly 21% over the last 30 days, declining from about $1.39 to a recent close near $1.10.
- A dilutive equity financing involving pre-funded warrants, disclosed in a mid-October filing, was a primary driver of the sharpest single-session declines.
- Positive clinical momentum, including a Nature Medicine publication of ASPEN-06 data and Fast Track designations, provided partial support amid the volatility.
- Over the trailing quarter, the stock has fallen approximately 44%, reflecting persistent pressure on small-cap clinical-stage biotech.
- Wall Street coverage remains largely constructive, with a consensus Strong Buy rating and an average price target well above the current share price.
- For more detail on this ticker's Price Targets, Earnings, and Forecast, explore the dedicated analysis pages.
- Explore Trending AI Robots to see how automated strategies are positioning across the market.
ALX Oncology Holdings (ALXO) Company Overview and Market Position
ALX Oncology Holdings Inc. is a clinical-stage immuno-oncology company headquartered in South San Francisco, California. Its lead program, evorpacept, is a CD47-blocking therapeutic being developed as a combination therapy for solid tumors and blood cancers. The company's most advanced study, ASPEN-06, is a Phase 2 trial evaluating evorpacept in HER2-positive gastric and gastroesophageal junction cancer, while the ASPEN-09 program targets breast cancer. A second, earlier-stage asset, ALX2004, is a differentiated EGFR-targeting antibody-drug conjugate in Phase 1 development for solid tumors.
The company operates through clinical collaborations rather than commercial revenue, including combination programs with Jazz Pharmaceuticals (zanidatamab) and Sanofi (isatuximab), and has received FDA Fast Track designations across multiple indications. As a pre-revenue biotech, ALX Oncology is followed closely for its clinical data readouts, cash runway, and financing activity rather than traditional earnings metrics. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
ALX Oncology Holdings (ALXO) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, ALXO declined approximately 21%, moving from a closing price near $1.39 to a recent close around $1.10. The move was not a straight line: shares drifted lower through early October, then fell sharply in mid-October before partially recovering into the high-$1.10s to low-$1.20s and settling near $1.10.
The quarterly picture is even steeper. From roughly $2.00 in late July, the stock has fallen about 44%, extending a multi-month downtrend. The 52-week range spans approximately $0.86 to $2.66, underscoring the elevated volatility that has characterized the name. With a market capitalization near $150 million, the stock remains firmly in small-cap, high-beta territory.
What Drove ALXO Stock Price in the Last 30 Days
The defining catalyst of the past month was a dilutive financing. In mid-October, the company filed an 8-K disclosing pre-funded warrants to purchase common stock, signaling a capital raise that pressured the share price. The stock fell sharply around the filing date, dipping below $0.90 intraday, before recovering as investors absorbed the announcement.
Offsetting that pressure were several positive developments. The company announced a Nature Medicine publication of ASPEN-06 Phase 2 data demonstrating strong responses and durable clinical benefit for evorpacept in HER2-positive gastric cancer. Wall Street also remained supportive, with Wells Fargo maintaining a Buy rating and a $5 price target and H.C. Wainwright reiterating a Buy rating with a $4 target during the period. Broader macro conditions added to the headwind: elevated Treasury yields and weak risk appetite for clinical-stage biotech weighed on the sector, amplifying downside moves in thinly traded names. From what I see, this mix of news created the kind of choppy action typical in small-cap biotechs.
What Drove ALXO Stock Performance Over the Last Quarter
Over the trailing quarter, ALXO's decline reflected a combination of company-specific financing risk and a challenging environment for pre-revenue biotech. The company reported second-quarter results showing a narrowing GAAP net loss, and presented additional evorpacept data at the ESMO Breast 2026 meeting, which highlighted CD47 expression as a predictive biomarker. However, concerns about cash runway and the prospect of additional equity raises consistently pressured sentiment, particularly after the mid-October financing announcement.
The broader narrative is one of a company advancing a differentiated immuno-oncology pipeline while operating with a limited cash position. That tension—meaningful clinical potential versus near-term dilution risk—has kept the stock under sustained pressure even as analyst price targets remain far above current levels. I reviewed the forecasts on Tickeron as well to cross-check the longer-term setup.
ALXO Stock Forecast Drivers: What Investors Should Watch Next
The most immediate catalyst is the company's next quarterly earnings report, expected in early November, where management commentary on cash runway and clinical timelines will be closely scrutinized. Investors should also monitor the ASPEN-09 Phase 2 breast cancer study, with topline data guided for mid-2027, and the ALX2004 Phase 1 dose-escalation readout. Financing activity remains a key risk: further capital raises could renew dilution concerns, while positive data readouts or partnership milestones could offset that pressure. Regulatory developments, including existing Fast Track designations, and the broader rate environment for small-cap biotech will also shape the stock's trajectory. These factors are informational only and do not constitute investment recommendations.
Using AI Tools in Biotech Research
In my view, automated platforms can add useful context when evaluating volatile names like this one. I often turn to Tickeron’s Trending AI Robots to observe how algorithmic strategies are currently positioned across similar small-cap biotech stocks. The page surfaces top-performing bots from a much larger universe, highlighting different approaches, holding periods, and risk profiles. This gives a practical, data-driven complement to manual analysis without replacing it. It is a focused way to see how these systems are navigating the current environment for clinical-stage companies.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ALXO's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for ALXO turned positive on October 19, 2026. Looking at past instances where ALXO's MACD turned positive, the stock continued to rise in 36 of 40 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ALXO's RSI Indicator exited the oversold zone, 39 of 44 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 89%.
Following a +16.98% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALXO advanced for three days, in 214 of 250 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
ALXO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 39 of 46 cases where ALXO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 85%.
The Momentum Indicator moved below the 0 level on October 23, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ALXO as a result. In 75 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.
The 50-day moving average for ALXO moved below the 200-day moving average on October 05, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALXO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for ALXO entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 84 (best 1 - 100 worst), indicating slightly worse than average price growth. ALXO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 92 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.117) is normal, around the industry mean (3.037). P/E Ratio (-0.957) is within average values for comparable stocks, (-1.223). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.883) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.237).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALXO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a clinical stage company, which engages in the research and development of therapies for cancer patients
Industry Biotechnology
Advertisement